Bevacizumab Biosimilar Vial for Oncology from Japan
Avastin biosimilar bevacizumab, a VEGF monoclonal antibody in 100mg/4ml vials for retail infusion in cancer treatment, modulating angiogenesis via immune regulation. Fits HTS 3002.15.00.91 for MAB immunological products in measured doses.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Biosimilars need comparative efficacy data; FDA 351(k) pathway docs essential
• Use insulated packaging with data loggers for uninterrupted cold chain